Focus

Since the number of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel tools is a prerequisite for success. Aglaia’s focus on oncology is considered to be a differentiating asset for scientists who see their discoveries being evaluated by leading scientists and businessmen from their own research field. After it has been decided to further develop the research findings in a dedicated venture, Aglaia’s professionals add substantial value through their knowledge, experience and network.

We seek to invest in novel tools and techniques as well as components of contemporary drug development, such as:

new production and selection systems for biomedical products new vectors and vehicles for drug delivery and drug targeting new diagnostic tools and essays new micro-array applications new screening assays (for diseases as well as for drug activity) new drug targets new drugs and drug systems

Our focus is on venturing instead of licensing-out the results of outstanding biomedical research. Encapsulating promising research results in a professional business environment markedly increases the chances of successful product development.

We invest primarily in opportunities from Dutch research institutes. However, we are open to discuss exceptional opportunities with international partners, in those situations where synergetic effects with other investments can be realized.